Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2013) 32 P1098 | DOI: 10.1530/endoabs.32.P1098

ECE2013 Poster Presentations Thyroid cancer (64 abstracts)

Examination of CYP24A1 and ‘three-genes' (SFN, MRC2, HMGA2) expressions in different pathological subgroups of human papillary thyroid cancer

Bernadett Balla 1 , János Kósa 1 , Bálint Tóbiás 1 , István Takács 1 , Zsolt Nagy 1 , Péter Horváth 1 , János Horányi 2 , Eszter Székely 3 , Balázs Járay 3 & Péter Lakatos 1

11st Department of Internal Medicine, Semmelweis University, Budapest, Hungary; 21st Department of Surgery, Semmelweis University, Budapest, Hungary; 32nd Department of Pathology, Semmelweis University, Budapest, Hungary.

Background: The ’three-genes’ (SFN, MRC2, HMGA2) might have direct role in various cancer progression and malignant thyroid conditions. We previously reported an increased expression of 1,25-D3 neutralizing enzyme, (24-hydroxylase – CYP24A1) as a possible novel marker gene in thyroid carcinoma. In this study, we examined the transcription activity of CYP24A1 and ‘three-genes’ in four functional subgroups of papillary thyroid tumor (PTC).

Methods: The gene expression analyses of more than 50 thyroid carcinoma/normal tissue pairs were carried out. Subgroups were defined by the following criteria: i) presence of somatic oncogene mutation and/or rearrangement; ii) conventional PTC or other PTC variants; iii) other thyroid disease present beside PTC; iv) lymphnode metastasis and/or vascular invasion are detected.

Results: We demonstrated that ‘three-genes’ expression was increased in 79.6% of PTC tissues that increased to 87.1% if CYP24A1 expression was added as a fourth gene. In group 1, higher rate of elevated ‘three-genes’ activities were seen if tumor tissues carried a somatic oncogene mutation. However, there is no difference in distribution of high-level CYP24A1 tumors between carriers and non-carriers. In group 2, we showed increased CYP24A1 expression ratio in conventional PTC samples vs PTC variants. No significant alteration was seen in proportion of enhanced ‘three-genes’ expression. In group 3, we observed greater ratio of CYP24A1 overexpressed tumors in PTC samples without any other thyroid disease. In group 4, higher percentage of tumor samples showed increased expression of all the examined genes if lymphnode metastasis and/or vascular invasion were detected.

Conclusions: Our results suggest that ‘three-genes’ model completed with CYP24A1 might increase the efficiency of molecular diagnosis of papillary thyroid cancer. Also, we have demonstrated that certain pathological states within PTC are associated with altered gene expression.

Article tools

My recent searches

No recent searches.